How Kevin Rocco Built the BioRez ConMed Acquisition Into a $250M Sports Medicine Exit

Key Takeaways

• ConMed acquired BioRez in a cash-free debt-free deal worth roughly $85M at closing plus $165M in growth-based earnouts across four years
• Kevin Rocco is structurally unusual in medtech: a technical founder who stayed through clinical trials, commercial launch, and exit instead of handing off at each transition
• The BioRez scaffold for sports medicine had genuine surgeon demand before commercial launch, peer-reviewed articles in Journal of Orthopedic Experience & Innovation predated revenue
• The exit pattern works for specialty-surgery medtech where deep surgeon advisory board engagement pre-launch produces post-launch pull-through
• Founders evaluating ConMed-style specialty acquirers should weigh earnout structure carefully: the $165M back half depends on commercial execution after close

In May 2024, ConMed announced the acquisition of BioRez In August 2022. The deal split into roughly $85 million in cash at close and $165 million in growth-based earnouts over four years.

The transaction closed a 14-year arc that started in a Yale engineering lab and ended with one of the cleaner specialty-surgery acquisitions of the recent vintage.

This post walks through the BioRez ConMed acquisition decision-by-decision. The engineering founder's path through clinical trials and commercial scale. The peer-reviewed publication trail that produced genuine surgeon pull before launch.

The deal structure ConMed offered and what the earnout architecture says about specialty-acquirer behaviour. And what sports-medicine and specialty-surgery medtech founders should take from how Kevin Rocco built the exit.

The Engineering Founder Who Stayed Through Exit

The first thing that makes the BioRez ConMed acquisition structurally interesting is Kevin Rocco's profile. Most medtech exits involve a founder handing off to a commercial CEO at one of three transitions: clinical-to-regulatory, regulatory-to-commercial, or commercial-to-exit. Kevin stayed through all three.

I interviewed Kevin Rocco on an episode about the $250M medtech exit with the founder of BioRez. On the same episode, I described his profile directly to him:

"It's rare to find a technical founder who invents a device or medical technology starts the company but then Shepherds it through its commercial phase into its exit usually there's a change and so Kevin you're kind of a you're like this rare gem of a unicorn."

So the structural significance of Kevin's profile is that it compresses the institutional knowledge transfer that usually destroys multiple at the regulatory-to-commercial transition.

When the founder hands off to a commercial CEO at clearance, the commercial leader has to rebuild the surgeon relationships, the clinical narrative, and the trial-data interpretation from the documentation the founder leaves behind. The transfer is never lossless. Multiple compresses every time.

Kevin staying through all three transitions kept the institutional knowledge intact. The surgeons who'd been on the advisory board pre-clinical were the same surgeons who became the first commercial accounts.

The clinical narrative built around the scaffold during animal studies became the commercial narrative. And the founder's relationship with ConMed during exit negotiations was the same relationship he'd been building across the industry for over a decade.

That continuity isn't replicable for every founder. But for technical founders who want to stay through exit, Kevin's path is a useful template for what the founder evolution requires.

The Pre-Launch Surgeon Demand That Made Commercial Easy

The second piece of the BioRez ConMed acquisition that's worth studying is how Kevin engineered genuine surgeon demand before the product had revenue. By the time BioRez launched commercially, the surgeon community in sports medicine was actively waiting for the scaffold.

I interviewed Dr. Ira Kirsch on an episode about Journal of Orthopedic Experience and Innovation updates. Ira walked through the publication trail that established the scaffold's credibility:

"Kevin Rocco from biorez he trained as an engineer um at a very small unknown College in New Haven called Yale um and he invented this in a lab this this is an improved scaffold that that we've had two three articles in Joey on use of that scaffold."

So the peer-reviewed publication trail predated commercial launch. Two to three articles in Journal of Orthopedic Experience and Innovation meant that the sports-medicine surgeon community had read about the scaffold, seen the early clinical evidence, and started talking about it in surgeon-to-surgeon conversations months before BioRez had a sales rep in the field.

On the BioRez exit episode, I described the downstream surgeon pull from the publication trail:

"This is the one that I've seen so many surgeons post about in the orthopedic space they just love this product. He's a technical founder meaning that he has a a degree in biomedical engineering so he was the technical founder of bioer but then also molded himself and merged."

So when BioRez did launch commercially, the surgeon community was primed. Reps didn't have to introduce the scaffold for the first time. They had to operationalise the demand that already existed. That sequencing is what produced the rapid revenue ramp post-launch and the strong commercial metrics ConMed saw during diligence.

For more on how pre-launch surgeon advisory board work compounds into post-launch commercial outcomes, see how to hire your first medical device sales rep, which covers Kevin's broader hiring sequence from the same exit conversation.

Why ConMed Structured BioRez as 85M Cash Plus 165M Earnout

The transaction structure ConMed offered tells a useful story about specialty-acquirer behaviour. The headline number is $250M. The reality is $85M at close and $165M conditional.

I covered the deal structure directly:

"In a cashfree debt-free basis for cast considerations of about 85 million at closing which is subject to adjustment but then also an additional $165 million in growth-based earnout payment over a 4-year period."

So 34% of the deal value lands at close. The remaining 66% depends on commercial execution over four years post-close. That ratio is heavier on earnouts than typical medtech transactions, which tend to land 50% to 70% of value at close.

The earnout-heavy structure says two things about ConMed's view of BioRez. First, ConMed believed the commercial potential was genuine but wanted to underwrite the execution risk by tying meaningful value to performance metrics they could measure post-close.

Second, the BioRez team was confident enough in their post-close commercial execution to accept the earnout structure rather than push for a higher cash component at lower total value.

The trade matters because earnout structures shape post-close team behaviour. The BioRez team had material financial incentive to hit the commercial milestones across the four-year period, which kept the institutional knowledge engaged inside ConMed for years rather than producing the immediate departure that all-cash deals often produce.

The Founder's Reflection on Exit

The same exits episode captured Kevin's own framing of what the exit felt like and what he was most proud of:

"You create a company you spend a long time you put all your Blood Sweat and Tears into it um you know it's cliche but it is like kind of raising a baby and and to kind of sell it off is is not easy. The we had a young smart Dynamic team you know at bioz I'm really really proud."

The "raising a baby" framing is well-worn but the second half of the quote is the one founders should study. The pride in the team is what made the earnout structure workable.

Kevin wasn't trying to maximise the close-day cheque and walk. He wanted the team he'd built to have a credible commercial home, which is what ConMed structurally offered (specialty acquirer, sports medicine portfolio, room to scale the scaffold across additional indications).

That trade is the specialty-acquirer pitch in summary. Smaller deal value than a generalist strategic might offer. Better commercial platform for the specific technology. Stronger team continuity post-close. Founders who care about the long arc of the technology and the team often prefer this trade despite the headline-number compression.

What Sports-Medicine and Specialty-Surgery Founders Should Take

The BioRez ConMed acquisition pattern is transferable for specialty-surgery medtech founders willing to commit to four discipline points.

The first discipline is the engineering-founder-through-exit path. Most founders don't have to stay through all three transitions (clinical to regulatory to commercial to exit), but the founders who do preserve institutional knowledge that compounds into exit multiple. Founders who hand off at each transition pay an information-transfer tax at each handoff.

The second discipline is the publication trail. Peer-reviewed clinical articles in specialty journals produce the surgeon-to-surgeon conversation that primes commercial demand before reps are in the field. Two to three solid articles in a specialty journal can compress commercial ramp by 12 to 18 months versus launching cold.

The third discipline is the specialty-acquirer screen. Smaller specialty acquirers where the technology sits at the centre of the strategy often produce better all-in outcomes than large generalist strategic acquirers paying higher headline numbers. The earnout architecture is the practical lever that aligns interests post-close.

The fourth discipline is the team-first negotiation posture. Founders who optimise for team continuity rather than close-day cash often get structures that work better for everyone over the four-year earnout window. The BioRez exit was a clean example of that posture producing material founder outcomes.

For more on the broader pattern across the largest medtech exits, see the medtech exit playbook. And for the operator framing of how Ray Cohen built the $3.7B Axonics exit on similar specialty-acquirer principles, see how Ray Cohen engineered 20 consecutive winning quarters.

What This Means for Medtech Founders

In my experience working with sports-medicine and specialty-surgery founders, the exit conversation often defaults to the largest possible acquirer at the highest possible headline number. The BioRez pattern argues for a different lens.

The right acquirer is the one where the technology will get rep attention, the surgeons who built the demand will stay engaged with the product, and the earnout structure rewards the team for the commercial execution they're best positioned to deliver.

So the better practice is to map the specialty acquirers in the category three years before the exit window and start the relationship work then. ConMed didn't appear out of nowhere when BioRez was ready to sell.

Kevin had been building specialty-acquirer relationships across the sports-medicine landscape for years. The acquirer that paid the $250M was the one with the best strategic fit, not the one who happened to call first.

Frequently Asked Questions

When did ConMed acquire BioRez?

ConMed announced the acquisition of BioRez in May 2024. The deal closed shortly thereafter on a cash-free, debt-free basis. Approximately $85 million was paid at closing, with an additional $165 million structured as growth-based earnout payments over a four-year period. The total potential transaction value was approximately $250 million.

What did BioRez make?

BioRez developed a biologic scaffold technology for sports medicine and orthopaedic soft tissue repair. The scaffold was invented in a Yale University engineering lab by Kevin Rocco, who served as the company's founder and CEO from incorporation through the ConMed acquisition.

The technology produced clinical results that were documented in multiple peer-reviewed articles in the Journal of Orthopedic Experience and Innovation, which built surgeon demand for the product before commercial launch.

Why was the BioRez ConMed acquisition earnout structure heavier than typical medtech deals?

The 34% cash at close versus 66% conditional earnout structure was heavier on earnouts than typical medtech transactions, which usually land 50% to 70% of deal value at close.

The structure reflected ConMed's confidence in the underlying commercial potential paired with a desire to underwrite execution risk by tying meaningful value to post-close performance metrics.

BioRez's team was confident enough in their post-close commercial execution to accept the earnout structure rather than push for a higher cash component at lower total value.

What can sports medicine medtech founders learn from the BioRez ConMed acquisition?

The four transferable lessons are: stay through commercial transitions to preserve institutional knowledge that compounds into exit multiple, build a peer-reviewed publication trail in specialty journals to generate surgeon-to-surgeon conversation before launch, screen for specialty acquirers where the technology sits at the centre of the strategy rather than larger generalist strategics, and adopt a team-first negotiation posture that often produces better all-in outcomes than close-day cash maximisation.

Listen to the Full Conversations

The episodes referenced in this post are available on The State of MedTech. Subscribe wherever you listen to podcasts.

• $250M MedTech Exit with Kevin Rocco, Founder of BioRez
• Journal of Orthopedic Experience & Innovation Updates with Dr. Ira Kirsch

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.